Abstract
Mitofusin-2 (MFN2) is a mitochondrial protein associated with mitochondrial fusion process. It was initially identified as a hyperplasia suppressor and implicated in Charcot–Marie–Tooth disease. Recent studies showed that MFN2 played important roles in the development of multiple tumors. Here we examined MFN2 expression in 30 lung adenocarcinoma samples and revealed that the expression of MFN2 was significantly higher in lung adenocarcinoma tissues as compared to adjacent normal tissues. We then investigated the impact of MFN2 knockdown on A549 human lung adenocarcinoma cells and showed that cell proliferation, cell cycle and invasion behavior were all deregulated by MFN2 knockdown. And deregulation of cell cycle pathway after MFN2 knockdown was confirmed by microarray analysis. Furthermore, microarray analysis also revealed that different oncogenes such as RAP1A, RALB and ITGA2 were oppositely regulated by MFN2, which provided molecular clues for the paradoxical functions of MFN2 in tumor development. Taken together, our study unraveled the tumor-promoting functions of MFN2 in lung adenocarcinoma and implicated that the role of MFN2 in cancer development might be more complicated than expected and should be explored in detail in the future.
Similar content being viewed by others
References
Cagle PT, Allen TC, Beasley MB, Chirieac LR, Dacic S, Borczuk AC, et al. Molecular pathology of lung cancer. Molecular pathology library. New York: Springer; 2012.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer J Int du Cancer. 2010;127(12):2893–917. doi:10.1002/ijc.25516.
Minna JD. Molecular pathogenesis of lung cancer with translation to the clinic [videorecording]. New Haven: MedMedia Services, Yale University School of Medicine, 2007.
Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012;150(6):1107–20. doi:10.1016/j.cell.2012.08.029.
Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543–50. doi:10.1038/nature13385.
Li L, Wei Y, To C, Zhu CQ, Tong J, Pham NA, et al. Integrated Omic analysis of lung cancer reveals metabolism proteome signatures with prognostic impact. Nat Commun. 2014;5:5469. doi:10.1038/ncomms6469.
Santel A, Fuller MT. Control of mitochondrial morphology by a human mitofusin. J Cell Sci. 2001;114(Pt 5):867–74.
Chen KH, Guo X, Ma D, Guo Y, Li Q, Yang D, et al. Dysregulation of HSG triggers vascular proliferative disorders. Nat Cell Biol. 2004;6(9):872–83. doi:10.1038/ncb1161.
Zuchner S, Mersiyanova IV, Muglia M, Bissar-Tadmouri N, Rochelle J, Dadali EL, et al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet. 2004;36(5):449–51. doi:10.1038/ng1341.
Bach D, Pich S, Soriano FX, Vega N, Baumgartner B, Oriola J, et al. Mitofusin-2 determines mitochondrial network architecture and mitochondrial metabolism. A novel regulatory mechanism altered in obesity. J Biol Chem. 2003;278(19):17190–7. doi:10.1074/jbc.M212754200.
Hernandez-Alvarez MI, Thabit H, Burns N, Shah S, Brema I, Hatunic M, et al. Subjects with early-onset type 2 diabetes show defective activation of the skeletal muscle PGC-1 alpha/mitofusin-2 regulatory pathway in response to physical activity. Diabetes Care. 2010;33(3):645–51. doi:10.2337/Dc09-1305.
Chien KR, Hoshijima M. Unravelling Ras signals in cardiovascular disease. Nat Cell Biol. 2004;6(9):807–8. doi:10.1038/Ncb904-807.
Wu L, Li ZX, Zhang YM, Zhang P, Zhu XH, Huang J, et al. Adenovirus-expressed human hyperplasia suppressor gene induces apoptosis in cancer cells. Mol Cancer Ther. 2008;7(1):222–32. doi:10.1158/1535-7163.Mct-07-0382.
Jin BY, Fu GH, Pan H, Cheng XF, Zhou L, Lv J, et al. Anti-tumour efficacy of mitofusin-2 in urinary bladder carcinoma. Med Oncol. 2011;28:S373–80. doi:10.1007/s12032-010-9662-5.
Wang WL, Lu JJ, Zhu F, Wei JF, Jia CK, Zhang YB, et al. Pro-apoptotic and anti-proliferative effects of mitofusin-2 via Bax signaling in hepatocellular carcinoma cells. Med Oncol. 2012;29(1):70–6. doi:10.1007/s12032-010-9779-6.
Haapa-Paananen S, Kiviluoto S, Waltari M, Puputti M, Mpindi JP, Kohonen P, et al. HES6 gene is selectively overexpressed in glioma and represents an important transcriptional regulator of glioma proliferation. Oncogene. 2012;31(10):1299–310. doi:10.1038/Onc.2011.316.
Ying J, Guo L, Qiu T, Shan L, Ling Y, Liu X, et al. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. Ann Oncol. 2013;24(10):2589–93. doi:10.1093/annonc/mdt295.
Wang L, Zhou GB, Liu P, Song JH, Liang Y, Yan XJ, et al. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci USA. 2008;105(12):4826–31. doi:10.1073/pnas.0712365105.
Sasaki K, Tsuno NH, Sunami E, Tsurita G, Kawai K, Okaji Y, et al. Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells. BMC Cancer. 2010;10:370. doi:10.1186/1471-2407-10-370.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. doi:10.1016/j.cell.2011.02.013.
Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer. 2003;3(5):362–74. doi:10.1038/nrc1075.
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–500. doi:10.1126/science.1099314.
Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693–703. doi:10.1056/NEJMoa1006448.
Drilon A, Wang L, Hasanovic A, Suehara Y, Lipson D, Stephens P, et al. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov. 2013;3(6):630–5. doi:10.1158/2159-8290.CD-13-0035.
Xia Y, Wu Y, He X, Gong J, Qiu F. Effects of mitofusin-2 gene on cell proliferation and chemotherapy sensitivity of MCF-7. J Huazhong Univ Sci Technol [Med Sci]. 2008;28(2):185–9. doi:10.1007/s11596-008-0218-2.
Ma L, Liu Y, Geng C, Qi X, Jiang J. Estrogen receptor beta inhibits estradiol-induced proliferation and migration of MCF-7 cells through regulation of mitofusin 2. Int J Oncol. 2013;42(6):1993–2000. doi:10.3892/ijo.2013.1903.
Zhang GE, Jin HL, Lin XK, Chen C, Liu XS, Zhang Q, et al. Anti-tumor effects of mfn2 in gastric cancer. Int J Mol Sci. 2013;14(7):13005–21. doi:10.3390/ijms140713005.
Wang W, Zhou D, Wei J, Wu Z, Cheng X, Sun Q, et al. Hepatitis B virus X protein inhibits p53-mediated upregulation of mitofusin-2 in hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2012;421(2):355–60. doi:10.1016/j.bbrc.2012.04.015.
Wang W, Zhu F, Wang S, Wei J, Jia C, Zhang Y, et al. HSG provides antitumor efficacy on hepatocellular carcinoma both in vitro and in vivo. Oncol Rep. 2010;24(1):183–8.
Rehman J, Zhang HJ, Toth PT, Zhang Y, Marsboom G, Hong Z, et al. Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. FASEB J Off Publ Fed Am Soc Exp Biol. 2012;26(5):2175–86. doi:10.1096/fj.11-196543.
Raaijmakers JH, Bos JL. Specificity in Ras and Rap signaling. J Biol Chem. 2009;284(17):10995–9. doi:10.1074/jbc.R800061200.
Small molecules inhibit the RAS-like small GTPases RALA and RALB. Cancer Discov. 2014;4(11):1251. doi:10.1158/2159-8290.CD-RW2014-199.
Girotti MR, Fernandez M, Lopez JA, Camafeita E, Fernandez EA, Albar JP, et al. SPARC promotes cathepsin B-mediated melanoma invasiveness through a collagen I/alpha 2 beta 1 integrin axis. J Invest Dermatol. 2011;131(12):2438–47. doi:10.1038/Jid.2011.239.
Acknowledgments
This work was supported by the National Natural Science foundation of China (81201839 and 81101770), the Research Project of Shanghai Municipal Commission of Health and Family Planning (20124Y108), the Excellent Young Teachers Program of Shanghai Jiaotong University School of Medicine, the Science and Technology Foundation of Shanghai Chest Hospital (YZ12-03) and the National High Technology Research and Development Program (2008AA02Z441).
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Yuqing Lou, Rong Li have contributed equally to this work.
Rights and permissions
About this article
Cite this article
Lou, Y., Li, R., Liu, J. et al. Mitofusin-2 over-expresses and leads to dysregulation of cell cycle and cell invasion in lung adenocarcinoma. Med Oncol 32, 132 (2015). https://doi.org/10.1007/s12032-015-0515-0
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12032-015-0515-0